← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06803589

Growth Hormone for the Treatment of Gastroparesis

Trial Parameters

Condition Gastroparesis
Sponsor Mayo Clinic
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-10-22
Completion 2027-10
Interventions
Growth Hormone

Brief Summary

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Eligibility Criteria

Inclusion Criteria: * Symptoms \> 6 months that have not responded satisfactorily to standard treatment. * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21 Exclusion Criteria: * Known history of GH deficiency, hypothalamic or pituitary disease * Diabetes * Prior use of GH therapy * Age-adjusted low serum IGF1 * Women on oral estrogen therapy6 * Pregnancy or nursing * History of malignant solid tumors * Obesity (BMI \> 30)History of coronary and thromboembolic diseases. * History of sarcoidosis * History of pituitary surgery * History of thyroid nodules. * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. * Failure to give informed consent.

Related Trials